New advances in targeted gastric cancer treatment

World Journal of Gastroenterology

Volumn 22, Issue 30, 2016, Pages 6776-6799

  Lazar, Daniela Cornelia ^a   Taban, Sorina ^a   Cornianu, Marioara ^a   Faur, Alexandra ^a   Goldis, Adrian ^a  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Chemotherapy; Clinical trials; Gastric cancer; Helicobacter pylori infection; New treatment advances; Targeted therapy

Indexed keywords

BEVACIZUMAB; BRIVANIB; CAPECITABINE; CETUXIMAB; CISPLATIN; DOCETAXEL; DOVITINIB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FIGITUMUMAB; GEFITINIB; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN; LAPATINIB; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NIMOTUZUMAB; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PAZOPANIB; PERTUZUMAB; PLACEBO; RAMUCIRUMAB; RECOMBINANT ENDOSTATIN; REGORAFENIB; RILOTUMUMAB; SORAFENIB; SUNITINIB; TRASTUZUMAB; UNINDEXED DRUG; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY; SCATTER FACTOR RECEPTOR; SOMATOMEDIN C; VASCULOTROPIN A;

ADJUVANT CHEMORADIOTHERAPY; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; BREAST CANCER; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; DIGESTIVE SYSTEM PERFORATION; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ERADICATION THERAPY; ESOPHAGUS CANCER; EWING SARCOMA; GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA; GASTROINTESTINAL STROMAL TUMOR; GLIOBLASTOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HELICOBACTER INFECTION; HUMAN; HYPERTENSION; IMMUNOHISTOCHEMISTRY; KIDNEY CANCER; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG CANCER; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY (TOPIC); NON SMALL CELL LUNG CANCER; NONHUMAN; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; PANCREAS CANCER; PANCREATIC NEUROENDOCRINE TUMOR; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; SOFT TISSUE SARCOMA; SOLID TUMOR; STOMACH ADENOCARCINOMA; STOMACH CANCER; SURVIVAL TIME; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR VASCULARIZATION; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL CYCLE; DRUG EFFECTS; IMMUNOTHERAPY; PATHOLOGY; STOMACH NEOPLASMS;

ANTIBODIES, MONOCLONAL; APOPTOSIS; CELL CYCLE; HUMANS; IMMUNOTHERAPY; INSULIN-LIKE GROWTH FACTOR I; MOLECULAR TARGETED THERAPY; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, FIBROBLAST GROWTH FACTOR; STOMACH NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84982162734     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v22.i30.6776     Document Type: Review

References (266)

1. Ferro A, Peleteiro B, Malvezzi M, Bosetti C, Bertuccio P, Levi F, Negri E, La Vecchia C, Lunet N. Worldwide trends in gastric cancer mortality (1980-2011), with predictions to 2015, and incidence by subtype. Eur J Cancer 2014; 50: 1330-1344 [PMID: 24650579 DOI: 10.1016/j.ejca.2014.01.029]
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90 [PMID: 21296855 DOI: 10.3322/caac.20107]
3. Globocan 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. Available from: URL: Http://globocan.iarc.fr./Pages/fact sheets cancer.aspx
4. Crew KD, Neugut AI. Epidemiology of upper gastrointestinal malignancies. Semin Oncol 2004; 31: 450-464 [PMID: 15297938 DOI: 10.1053/j.seminoncol.2004.04.021]
5. Kubo A, Corley DA. Marked regional variation in adenocarcinomas of the esophagus and the gastric cardia in the United States. Cancer 2002; 95: 2096-2102 [PMID: 12412162 DOI: 10.1002/cncr.10940]
6. Parkin DM, Muir CS. Cancer Incidence in Five Continents. Comparability and quality of data. IARC Sci Publ 1992; (120): 45-173 [PMID: 1284606]
7. Malfertheiner P, Bornschein J, Selgrad M. Role of Helicobacter pylori infection in gastric cancer pathogenesis: A chance for prevention. J Dig Dis 2010; 11: 2-11 [PMID: 20132425 DOI: 10.1111/j.1751-2980.2009.00408.x]
8. Polk DB, Peek RM. Helicobacter pylori: Gastric cancer and beyond. Nat Rev Cancer 2010; 10: 403-414 [PMID: 20495574 DOI: 10.1038/nrc2857]
9. Brenner H, Arndt V, Stegmaier C, Ziegler H, Rothenbacher D. Is Helicobacter pylori infection a necessary condition for noncardia gastric cancer? Am J Epidemiol 2004; 159: 252-258 [PMID: 14742285 DOI: 10.1093/aje/kwh039]
10. Bornschein J, Selgrad M, Warnecke M, Kuester D, Wex T, Malfertheiner P. H. pylori infection is a key risk factor for proximal gastric cancer. Dig Dis Sci 2010; 55: 3124-3131 [PMID: 20668939 DOI: 10.1007/s10620-010-1351-x]
11. Take S, Mizuno M, Ishiki K, Nagahara Y, Yoshida T, Yokota K, Oguma K, Okada H, Shiratori Y. The effect of eradicating helicobacter pylori on the development of gastric cancer in patients with peptic ulcer disease. Am J Gastroenterol 2005; 100: 1037-1042 [PMID: 15842576 DOI: 10.1111/j.1572-0241.2005.41384.x]
12. Mera R, Fontham ET, Bravo LE, Bravo JC, Piazuelo MB, Camargo MC, Correa P. Long term follow up of patients treated for Helicobacter pylori infection. Gut 2005; 54: 1536-1540 [PMID: 15985559 DOI: 10.1136/gut.2005.072009]
13. You WC, Brown LM, Zhang L, Li JY, Jin ML, Chang YS, Ma JL, Pan KF, Liu WD, Hu Y, Crystal-Mansour S, Pee D, Blot WJ, Fraumeni JF, Xu GW, Gail MH. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J Natl Cancer Inst 2006; 98: 974-983 [PMID: 16849680 DOI: 10.1093/jnci/djj264]
14. Fuccio L, Zagari RM, Eusebi LH, Laterza L, Cennamo V, Ceroni L, Grilli D, Bazzoli F. Meta-analysis: Can Helicobacter pylori eradication treatment reduce the risk for gastric cancer? Ann Intern Med 2009; 151: 121-128 [PMID: 19620164 DOI: 10.7326/0003-48 19-151-2-200907210-00009]
15. de Vries AC, Meijer GA, Looman CW, Casparie MK, Hansen BE, van Grieken NC, Kuipers EJ. Epidemiological trends of premalignant gastric lesions: A long-term nationwide study in the Netherlands. Gut 2007; 56: 1665-1670 [PMID: 17698860 DOI: 10.1136/gut.2007.127167]
16. Lee YC, Chen TH, Chiu HM, Shun CT, Chiang H, Liu TY, Wu MS, Lin JT. The benefit of mass eradication of Helicobacter pylori infection: A community-based study of gastric cancer prevention. Gut 2013; 62: 676-682 [PMID: 22698649 DOI: 10.1136/gutjnl-2012-302240]
17. Correa P. Is gastric cancer preventable? Gut 2004; 53: 1217-1219 [PMID: 15306570 DOI: 10.1136/gut.2004.039834]
18. Cervantes A, Roda D, Tarazona N, Roselló S, Pérez-Fidalgo JA. Current questions for the treatment of advanced gastric cancer. Cancer Treat Rev 2013; 39: 60-67 [PMID: 23102520 DOI: 10.1016/j.ctrv.2012.09.007]
19. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64: 9-29 [PMID: 24399786 DOI: 10.3322/caac.21208]
20. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249 [PMID: 19474385]
21. Biondi A, Hyung WJ. Seventh edition of TNM classification for gastric cancer. J Clin Oncol 2011; 29: 4338-4339; author reply 4340-4342 [PMID: 22010017]
22. Washington K. 7th edition of the AJCC cancer staging manual: Stomach. Ann Surg Oncol 2010; 17: 3077-3079 [PMID: 20882416 DOI: 10.1245/s10434-010-1362-z]
23. Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, Nashimoto A, Fujii M, Nakajima T, Ohashi Y. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 2011; 29: 4387-4393 [PMID: 22010012 DOI: 10.1200/JCO.2011.36.5908]
24. Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, Lee KW, Kim YH, Noh SI, Cho JY, Mok YJ, Kim YH, Ji J, Yeh TS, Button P, Sirzén F, Noh SH. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): A phase 3 open-label, randomised controlled trial. Lancet 2012; 379: 315-321 [PMID: 22226517 DOI: 10.1016/S0140-6736(11)61873-4]
25. Ajani JA, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Awad L, Van Cutsem E. Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: The V-325 Study Group. J Clin Oncol 2007; 25: 3210-3216 [PMID: 17664468 DOI: 10.1200/JCO.2006.10.4968]
26. Kothari N, Almhanna K. Current status of novel agents in advanced gastroesophageal adenocarcinoma. J Gastrointest Oncol 2015; 6: 60-74 [PMID: 25642339 DOI: 10.3978/j.issn.2078-6891. 2014.098]
27. Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, Seeburg PH, Libermann TA, Schlessinger J, Francke U. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985; 230: 1132-1139 [PMID: 2999974 DOI: 10.1126/science.2999974]
28. Stintzing S, Jung A, Rossius L, Modest DP, von Weikersthal LF, Decker T, Kiani A, Al-Batran SE, Vehling-Kaiser U, Heintges T, Moehler M, Scheithauer W, Kirchner T, Heinemann V. Mutations within the EGFR signaling pathway: Influence on efficacy in FIRE-3-A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients. J Clin Oncol 2014; 32 Suppl 3: Abstr 445
29. Matsui Y, Inomata M, Tojigamori M, Sonoda K, Shiraishi N, Kitano S. Suppression of tumor growth in human gastric cancer with HER2 overexpression by an anti-HER2 antibody in a murine model. Int J Oncol 2005; 27: 681-685 [PMID: 16077916 DOI: 10.3892/ijo.27.3.681]
30. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687-697 [PMID: 20728210 DOI: 10.1016/S0140-6736(10)61121-X]
31. Clinical trials.gov. A study of trastuzumab emtansine versus taxane in patients with advanced gastric cancer. Available from: URL: Http://clinicaltrials.gov/show/NCT01641939
32. Clinical trials.gov. A study of capecitabine [xeloda] in combination with trastuzumab [herceptin] and oxaliplatine in patients with resectable gastric cancer. Available from: URL: Http://clinicaltrials.gov/show/NCT01130337
33. Clinical trials.gov. A study of the combination of oxaliplatin, capecitabine and herceptin (trastuzumab) and chemoradiotherapy in the adjuvant setting in operated patients with HER2 gastric or gastro-esophageal junction cancer (TOXAG study). Available from: URL: Http://www.clinicaltrials.gov/show/NCT01748773
34. Clinical trials.gov. Explorative phase II study of perioperative treatment in patients with adenocarcinoma of the gastroesophageal junction or stomach (HerFLOT). Available from: URL: Http://www.clinicaltrials.gov/ct2/show/NCT01472029
35. Clinical trials.gov. Radiation therapy, paclitaxel, and carboplatin with or without trastuzumab in treating patients with esophageal cancer. Available from: URL: Http://clinicaltrials.gov/show/NCT01196390
36. Ryu MH, Yoo C, Kim JG, Ryoo BY, Park YS, Park SR, Han HS, Chung IJ, Song EK, Lee KH, Kang SY, Kang YK. Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer. Eur J Cancer 2015; 51: 482-488 [PMID: 25661103 DOI: 10.1016/j.ejca.2014.12.015]
37. Kurokawa Y, Sugimoto N, Miwa H, Tsuda M, Nishina S, Okuda H, Imamura H, Gamoh M, Sakai D, Shimokawa T, Komatsu Y, Doki Y, Tsujinaka T, Furukawa H. Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1). Br J Cancer 2014; 110: 1163-1168 [PMID: 24473399 DOI: 10.1038/bjc.2014.18]
38. Hoff P, Tabernero J, Shen L. P-0111 Pertuzumab, trastuzumab and chemotherapy in HER2-positive metastatic gastric or gastrooesophageal junction cancer: An international phase III study (JACOB). Ann Oncol 2013; 24: Iv67 [DOI: 10.1093/annonc/mdt203.109]
39. Clinical trials.gov. A study of trastuzumab emtansine versus taxane in patients with advanced gastric cancer. Available from: URL: Http://clinicaltrials.gov/show/NCT01641939.
40. Cameron D, Casey M, Press M, Lindquist D, Pienkowski T, Romieu CG, Chan S, Jagiello-Gruszfeld A, Kaufman B, Crown J, Chan A, Campone M, Viens P, Davidson N, Gorbounova V, Raats JI, Skarlos D, Newstat B, Roychowdhury D, Paoletti P, Oliva C, Rubin S, Stein S, Geyer CE. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: Updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008; 112: 533-543 [PMID: 18188694 DOI: 10.1007/s10549-007-9885-0]
41. Accessdata.fda.gov. Administration US FDA. Lapatinib. Available from: URL: Http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/022059s016s017lbl.pdf 21-23
42. Hecht JR, Bang YJ, Qin SK, Chung HC, Xu JM, Park JO, Jeziorski K, Shparyk Y, Hoff PM, Sobrero A, Salman P, Li J, Protsenko SA, Wainberg ZA, Buyse M, Afenjar K, Houé V, Garcia A, Kaneko T, Huang Y, Khan-Wasti S, Santillana S, Press MF, Slamon D. Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC-A Randomized Phase III Trial. J Clin Oncol 2016; 34: 443-451 [PMID: 26628478 DOI: 10.1200/JCO.2015.62.6598]
43. Satoh T, Xu RH, Chung HC, Sun GP, Doi T, Xu JM, Tsuji A, Omuro Y, Li J, Wang JW, Miwa H, Qin SK, Chung IJ, Yeh KH, Feng JF, Mukaiyama A, Kobayashi M, Ohtsu A, Bang YJ. Lapatinib plus paclitaxel versus paclitaxel alone in the secondline treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN- A randomized, phase III study. J Clin Oncol 2014; 32: 2039-2049 [PMID: 24868024 DOI: 10.1200/JCO.2013.53.6136]
44. Clinical trials.gov. Cunningham D. Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric Cancer (ST03). Available from: URL: Https://clinicaltrials.gov/ct2/show/NCT00450203
45. Herbst RS. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys 2004; 59: 21-26 [PMID: 15142631 DOI: 10.1016/j.ijrobp.2003.11.041]
46. Oda K, Matsuoka Y, Funahashi A, Kitano H. A comprehensive pathway map of epidermal growth factor receptor signaling. Mol Syst Biol 2005; 1: 2005.0010 [PMID: 16729045 DOI: 10.1038/msb4100014]
47. Lieto E, Ferraraccio F, Orditura M, Castellano P, Mura AL, Pinto M, Zamboli A, De Vita F, Galizia G. Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients. Ann Surg Oncol 2008; 15: 69-79 [PMID: 17896140]
48. van Grieken NC, Aoyama T, Chambers PA, Bottomley D, Ward LC, Inam I, Buffart TE, Das K, Lim T, Pang B, Zhang SL, Tan IB, Carvalho B, Heideman DA, Miyagi Y, Kameda Y, Arai T, Meijer GA, Tsuburaya A, Tan P, Yoshikawa T, Grabsch HI. KRAS and BRAF mutations are rare and related to DNA mismatch repair deficiency in gastric cancer from the East and the West: Results from a large international multicentre study. Br J Cancer 2013; 108: 1495-1501 [PMID: 23511561 DOI: 10.1038/bjc.2013.109]
49. Martinelli E, De Palma R, Orditura M, De Vita F, Ciardiello F. Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. Clin Exp Immunol 2009; 158: 1-9 [PMID: 19737224 DOI: 10.1111/j.1365-2249.2009.03992.x]
50. Saltz LB, Lenz HJ, Kindler HL, Hochster HS, Wadler S, Hoff PM, Kemeny NE, Hollywood EM, Gonen M, Quinones M, Morse M, Chen HX. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: The BOND-2 study. J Clin Oncol 2007; 25: 4557-4561 [PMID: 17876013 DOI: 10.1200/JCO.2007.12.0949]
51. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N, Hitt R. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359: 1116-1127 [PMID: 18784101 DOI: 10.1056/NEJMoa0802656]
52. Lordick F, Kang YK, Chung HC, Salman P, Oh SC, Bodoky G, Kurteva G, Volovat C, Moiseyenko VM, Gorbunova V, Park JO, Sawaki A, Celik I, Götte H, Melezínková H, Moehler M. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): A randomised, open-label phase 3 trial. Lancet Oncol 2013; 14: 490-499 [PMID: 23594786 DOI: 10.1016/S1470-2045(13)70102-5]
53. Clinical trials.gov. Use of Cetuximab for Unresectable or Metastatic Esophageal and Gastric Cancer. Available from: URL: Https://www.clinicaltrials.gov/ct2/show/NCT00130689
54. Clinical trials.gov. Cetuximab, Cisplatin, and Irinotecan in Treating Patients With Metastatic Esophageal Cancer, Gastroesophageal Junction Cancer, or Gastric Cancer That Did Not Respond to Previous Irinotecan and Cisplatin. Available from: URL: Https://www.clinicaltrials.gov/ct2/show/NCT00397904
55. Clinical trials.gov. Pre-operation Chemo and Antibody Therapy Followed by Surgical Resection and Adjuvant Chemoradiation for Gastric Cancer. Available from: URL: Https://www.clinicaltrials. gov/ct2/show/NCT00857246
56. Clinical trials.gov. Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer. Available from: URL: Https://www.clinicaltrials.gov/ct2/show/study/NCT00397384
57. Pinto C, Di Fabio F, Barone C, Siena S, Falcone A, Cascinu S, Rojas Llimpe FL, Stella G, Schinzari G, Artale S, Mutri V, Giaquinta S, Giannetta L, Bardelli A, Martoni AA. Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study). Br J Cancer 2009; 101: 1261-1268 [PMID: 19773760 DOI: 10.1038/sj.bjc.6605319]
58. Tebbutt NC, Parry MM, Zannino D, Strickland AH, Van Hazel GA, Pavlakis N, Ganju V, Mellor D, Dobrovic A, Gebski VJ. Docetaxel plus cetuximab as second-line treatment for docetaxelrefractory oesophagogastric cancer: The AGITG ATTAX2 trial. Br J Cancer 2013; 108: 771-774 [PMID: 23412099 DOI: 10.1038/bjc.2013.41]
59. Kim C, Lee JL, Ryu MH, Chang HM, Kim TW, Lim HY, Kang HJ, Park YS, Ryoo BY, Kang YK. A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer. Invest New Drugs 2011; 29: 366-373 [PMID: 19997960 DOI: 10.1007/s10637-009-9363-0]
60. Waddell T, Chau I, Cunningham D, Gonzalez D, Okines AF, Okines C, Wotherspoon A, Saffery C, Middleton G, Wadsley J, Ferry D, Mansoor W, Crosby T, Coxon F, Smith D, Waters J, Iveson T, Falk S, Slater S, Peckitt C, Barbachano Y. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): A randomised, open-label phase 3 trial. Lancet Oncol 2013; 14: 481-489 [PMID: 23594787 DOI: 10.1016/S1470-2045(13)70096-2]
61. Clinical trials.gov. Perioperative Panitumumab and Epirubicin, Oxaliplatin and Xeloda (EOX) in Patients With Gastroesophageal Adenocarcinoma (EOXP). Available from: URL: Https://www. clinicaltrials.gov/ct2/show/results/NCT00667420
62. Clinical trials.gov. Panitumumab, Paclitaxel, Carboplatin and 5FU in the Treatment of Potentially Resectable Gastroesophageal Adenocarcinoma. Available from: URL: Https://www.clinicaltrials. gov/ct2/show/NCT01182610
63. Clinical trials.gov. ECX Panitumumab vs ECX Alone in Locally Advanced Gastric Cancer or Cancer of the Gastroesophageal Junction. Available from: URL: Https://www.clinicaltrials.gov/ct2/show/NCT01234324
64. Clinical trials.gov. MEGA (Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma): FOLFOX Alone or in Combination With AMG 102 or Panitumumab as First-line Treatment in Patients With Advanced Gastroesophageal Adenocarcinoma. Available from: URL: Https://www.clinicaltrials.gov/ct2/show/NCT01443065
65. Xu W, Yang Z, Lu N. Molecular targeted therapy for the treatment of gastric cancer. J Exp Clin Cancer Res 2016; 35: 1 [PMID: 26728266 DOI: 10.1186/s13046-015-0276-9]
66. Crombet T, Torres L, Neninger E, Catalá M, Solano ME, Perera A, Torres O, Iznaga N, Torres F, Pérez R, Lage A. Pharmacological evaluation of humanized anti-epidermal growth factor receptor, monoclonal antibody h-R3, in patients with advanced epithelialderived cancer. J Immunother 2003; 26: 139-148 [PMID: 12616105]
67. Crombet-Ramos T, Rak J, Pérez R, Viloria-Petit A. Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: A humanized anti-EGFR antibody. Int J Cancer 2002; 101: 567-575 [PMID: 12237899 DOI: 10.1002/ijc.10647]
68. Li K, Li J. Current Molecular Targeted Therapy in Advanced Gastric Cancer: A Comprehensive Review of Therapeutic Mechanism, Clinical Trials, and Practical Application. Gastroenterol Res Pract 2016; 2016: 4105615 [PMID: 26880889 DOI: 10.1155/2016/4105615]
69. Satoh T, Lee KH, Rha SY, Sasaki Y, Park SH, Komatsu Y, Yasui H, Kim TY, Yamaguchi K, Fuse N, Yamada Y, Ura T, Kim SY, Munakata M, Saitoh S, Nishio K, Morita S, Yamamoto E, Zhang Q, Kim JM, Kim YH, Sakata Y. Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as secondline therapy for patients with advanced gastric cancer. Gastric Cancer 2015; 18: 824-832 [PMID: 25185971 DOI: 10.1007/s10120-014-0420-9]
70. Clinical trials.gov. Phase 3 Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrect Gastric and Gastroesophageal Junction Cancer. Available from: URL: Https://www.clinicaltrials.gov/ct2/show/NCT01813253
71. Du F, Zheng Z, Shi S, Jiang Z, Qu T, Yuan X, Sun Y, Song Y, Yang L, Zhao J, Wang J, Chi Y. S-1 and Cisplatin With or Without Nimotuzumab for Patients With Untreated Unresectable or Metastatic Gastric Cancer: A Randomized, Open-Label Phase 2 Trial. Medicine (Baltimore) 2015; 94: E958 [PMID: 26061330 DOI: 10.1097/MD.0000000000000958]
72. Clinical trials.gov. Gefitinib in Combination With Chemoradiation in Resectable Gastric Cancer. Available from: URL: Https://www. clinicaltrials.gov/ct2/show?term=gefitinib, gastric cancer&rank=2
73. Clinical trials.gov. Cisplatin and Irinotecan Chemotherapy, Followed by ZD 1839 (Iressa) in Patients With Esophageal or Gastric Carcinomas. Available from: URL: Https://www. clinicaltrials.gov/ct2/show/NCT00215995
74. Clinical trials.gov. Gefitinib in treating pacients with esophageal cancer that is progressing after chemotherapy. Available from: URL: Http://www.clinicaltrials.gov/ct2/show/NCT01243398
75. Dragovich T, McCoy S, Fenoglio-Preiser CM, Wang J, Benedetti JK, Baker AF, Hackett CB, Urba SG, Zaner KS, Blanke CD, Abbruzzese JL. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol 2006; 24: 4922-4927 [PMID: 17050876 DOI: 10.1200/JCO.2006.07.1316]
76. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971; 285: 1182-1186 [PMID: 4938153 DOI: 10.1056/NEJM197111182852108]
77. Folkman J, Cole P, Zimmerman S. Tumor behavior in isolated perfused organs: In vitro growth and metastases of biopsy material in rabbit thyroid and canine intestinal segment. Ann Surg 1966; 164: 491-502 [PMID: 5951515]
78. Folkman J. The vascularization of tumors. Sci Am 1976; 234: 58-64, 70-3 [PMID: 1273568]
79. Folkman J. Anti-angiogenesis: New concept for therapy of solid tumors. Ann Surg 1972; 175: 409-416 [PMID: 5077799]
80. Folkman J, Long DM, Becker FF. Growth and metastasis of tumor in organ culture. Cancer 1963; 16: 453-467 [PMID: 13958548 DOI: 10.1002/1097-0142(196304)16: 4 3.0.CO;2-Y]
81. Dvorak HF, Sioussat TM, Brown LF, Berse B, Nagy JA, Sotrel A, Manseau EJ, Van de Water L, Senger DR. Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: Concentration in tumor blood vessels. J Exp Med 1991; 174: 1275-1278 [PMID: 1940805]
82. Ferrara N, Houck K, Jakeman L, Leung DW. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev 1992; 13: 18-32 [PMID: 1372863]
83. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995; 146: 1029-1039 [PMID: 7538264]
84. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997; 18: 4-25 [PMID: 9034784]
85. Peters KG, De Vries C, Williams LT. Vascular endothelial growth factor receptor expression during embryogenesis and tissue repair suggests a role in endothelial differentiation and blood vessel growth. Proc Natl Acad Sci USA 1993; 90: 8915-8919 [PMID: 7692439]
86. Gerber HP, Hillan KJ, Ryan AM, Kowalski J, Keller GA, Rangell L, Wright BD, Radtke F, Aguet M, Ferrara N. VEGF is required for growth and survival in neonatal mice. Development 1999; 126: 1149-1159 [PMID: 10021335]
87. Otani N, Minami S, Yamoto M, Shikone T, Otani H, Nishiyama R, Otani T, Nakano R. The vascular endothelial growth factor/fmslike tyrosine kinase system in human ovary during the menstrual cycle and early pregnancy. J Clin Endocrinol Metab 1999; 84: 3845-3851 [PMID: 10523040]
88. Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Dvorak HF, Senger DR. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol 1993; 143: 1255-1262 [PMID: 8238242]
89. Inoue M, Hager JH, Ferrara N, Gerber HP, Hanahan D. VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell 2002; 1: 193-202 [PMID: 12086877 DOI: 10.1016/S1535-6108(02)00031-4]
90. Gerber HP, Kowalski J, Sherman D, Eberhard DA, Ferrara N. Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Cancer Res 2000; 60: 6253-6258 [PMID: 11103779]
91. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-676 [PMID: 12778165 DOI: 10.1038/nm0603-669]
92. Kaipainen A, Korhonen J, Mustonen T, van Hinsbergh VW, Fang GH, Dumont D, Breitman M, Alitalo K. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci USA 1995; 92: 3566-3570 [PMID: 7724599]
93. Chang L, Kaipainen A, Folkman J. Lymphangiogenesis new mechanisms. Ann N Y Acad Sci 2002; 979: 111-119 [PMID: 12543721 DOI: 10.1111/j.1749-6632.2002.tb04872.x]
94. Levy AP, Levy NS, Goldberg MA. Post-transcriptional regulation of vascular endothelial growth factor by hypoxia. J Biol Chem 1996; 271: 2746-2753 [PMID: 8576250 DOI: 10.1074/jbc.271.5.2746]
95. Dor Y, Keshet E. Ischemia-driven angiogenesis. Trends Cardiovasc Med 1997; 7: 289-294 [PMID: 21235898 DOI: 10.1016/S1050-1738(97)00091-1]
96. Ferrara N. Role of vascular endothelial growth factor in regulation of angiogenesis. In: Teicher BA, editor. Antiangiogenic agents in cancer therapy. New Jersey: Humana Press, 1999: 119-142
97. Roberts WG, Palade GE. Neovasculature induced by vascular endothelial growth factor is fenestrated. Cancer Res 1997; 57: 765-772 [PMID: 9044858]
98. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003; 9: 653-660 [PMID: 12778163]
99. Grigore D, Simionescu CE, Stepan A, Margaritescu C, Balasoiu M, Georgescu CC, Cernea D, Dumitrescu D. Assessment of CD105, a-SMA and VEGF expression in gastric carcinomas. Rom J Morphol Embryol 2013; 54: 701-707 [PMID: 24322015]
100. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342 [PMID: 15175435 DOI: 10.1056/NEJMoa032691]
101. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666-2676 [PMID: 18160686 DOI: 10.1056/NEJMoa072113]
102. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-2550 [PMID: 17167137 DOI: 10.1056/NEJMoa061884]
103. Cannistra SA, Matulonis UA, Penson RT, Hambleton J, Dupont J, Mackey H, Douglas J, Burger RA, Armstrong D, Wenham R, McGuire W. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007; 25: 5180-5186 [PMID: 18024865 DOI: 10.1200/JCO.2007.12.0782]
104. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial. Lancet 2007; 370: 2103-2111 [PMID: 18156031 DOI: 10.1016/S0140-6736(07)61904-7]
105. Takano S, Ishikawa E, Nakai K, Matsuda M, Masumoto T, Yamamoto T, Matsumura A. Bevacizumab in Japanese patients with malignant glioma: From basic research to clinical trial. Onco Targets Ther 2014; 7: 1551-1562 [PMID: 25228814 DOI: 10.2147/OTT.S67621]
106. Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, Lim HY, Yamada Y, Wu J, Langer B, Starnawski M, Kang YK. Bevacizumab in combination with chemotherapy as firstline therapy in advanced gastric cancer: A randomized, doubleblind, placebo-controlled phase III study. J Clin Oncol 2011; 29: 3968-3976 [PMID: 21844504 DOI: 10.1200/JCO.2011.36.2236]
107. Shah M, Kang Y, Ohtsu A. Tumor and blood plasma biomarker analyses in the AVAGAST phase III randomized study of firstline bevacizumab capecitabine/cisplatin in patients with advanced gastric cancer. Ann Oncol 2010; 20 (Suppl 8): Abstr 174PD
108. Van Cutsem E, de Haas S, Kang YK, Ohtsu A, Tebbutt NC, Ming Xu J, Peng Yong W, Langer B, Delmar P, Scherer SJ, Shah MA. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: A biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol 2012; 30: 2119-2127 [PMID: 22565005 DOI: 10.1200/JCO.2011.39.9824]
109. Shen L, Li J, Xu J, Pan H, Dai G, Qin S, Wang L, Wang J, Yang Z, Shu Y, Xu R, Chen L, Liu Y, Yu S, Bu L, Piao Y. Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: Randomized, double-blind, phase III study (AVATAR study). Gastric Cancer 2015; 18: 168-176 [PMID: 24557418 DOI: 10.1007/s10120-014-0351-5]
110. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20 [PMID: 16822992 DOI: 10.1056/NEJMoa055531]
111. Choi AH, Kim J, Chao J. Perioperative chemotherapy for resectable gastric cancer: MAGIC and beyond. World J Gastroenterol 2015; 21: 7343-7348 [PMID: 26139980 DOI: 10.3748/wjg.v21.i24.7343]
112. Clinical trials.gov. Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer. Available from: URL: Https://clinicaltrials.gov/ct2/show/NCT00394433
113. Clinical trials.gov. Efficacy of Docetaxel, Capecitabine, Cisplatin, and Bevacizumab in Patients With Unresectable Advanced Gastric Cancer. Available from: URL: Https://clinicaltrials.gov/ct2/show/NCT01471470
114. Clinical trials.gov. Cisplatin, Irinotecan and Bevacizumab (PCA) Versus Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer. Available from: URL: Https://clinicaltrials.gov/ct2/show/NCT00911820
115. Clinical trials.gov. Docetaxel, Oxaliplatin, Capecitabine, Bevacizumab and Trastuzumab in Patients With Locally Advanced or Metastatic Gastric Cancer (B-DOCT). Available from: URL: Https://clinicaltrials.gov/ct2/show/NCT01359397
116. Clinical trials.gov. CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer. Available from: URL: Https://clinicaltrials.gov/ct2/show/ NCT01191697
117. Clinical trials.gov. Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer. Available from: URL: Https://clinicaltrials.gov/ct2/show/NCT01212822
118. Clinical trials.gov. Pre-operative Chemotherapy Plus Bevacizumab With Early Salvage Therapy Based on PET Assessment of Response in Patients With Locally Advanced But Resectable Gastric and GEJ Adenocarcinoma. Available from: URL: Https://clinicaltrials.gov/ct2/show/NCT00737438
119. Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, Safran H, dos Santos LV, Aprile G, Ferry DR, Melichar B, Tehfe M, Topuzov E, Zalcberg JR, Chau I, Campbell W, Sivanandan C, Pikiel J, Koshiji M, Hsu Y, Liepa AM, Gao L, Schwartz JD, Tabernero J. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): An international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014; 383: 31-39 [PMID: 24094768 DOI: 10.1016/S0140-6736(13)61719-5]
120. Accessdata.fda.gov. Administration US FDA. Ramucirumab. Available from: URL: Http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/125477lbl.pdf
121. Wilke H, Van Cutsem E, Oh SC. RAINBOW: A global, phase 3, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of metastatic gastric adenocarcinoma following disease progression on firstline platinum- And fluoropyrimidinecontaining combination therapy: Results of a multiple Cox regression analysis adjusting for prognostic factors. J Clin Oncol 2014; 32: Abstr 4076
122. Casak SJ, Fashoyin-Aje I, Lemery SJ, Zhang L, Jin R, Li H, Zhao L, Zhao H, Zhang H, Chen H, He K, Dougherty M, Novak R, Kennett S, Khasar S, Helms W, Keegan P, Pazdur R. FDA Approval Summary: Ramucirumab for Gastric Cancer. Clin Cancer Res 2015; 21: 3372-3376 [PMID: 26048277 DOI: 10.1158/1078-0432]
123. Yoon HH, Bendell JC, Braiteh FS. Ramucirumab (RAM) plus FOLFOX as front-line therapy (Rx) for advanced gastric or esophageal adenocarcinoma (GE-AC): Randomized, double-blind, multicenter phase 2 trial. J Clin Oncol 2014; 32: Abstr 4004
124. Ling Y, Yang Y, Lu N, You QD, Wang S, Gao Y, Chen Y, Guo QL. Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells. Biochem Biophys Res Commun 2007; 361: 79-84 [PMID: 17644065 DOI: 10.1016/j.bbrc.2007.06.155]
125. Xu R, Ma N, Wang F, Ma L, Chen R, Chen R, Kebinu M, Ma L, Han Z, Ayixiamu M, Su P, Naman Y, Jieensi H, Yang H, Adili A, Aili S, Liu J. Results of a randomized and controlled clinical trial evaluating the efficacy and safety of combination therapy with Endostar and S-1 combined with oxaliplatin in advanced gastric cancer. Onco Targets Ther 2013; 6: 925-929 [PMID: 23926435 DOI: 10.2147/OTT.S46487]
126. Geng R, Li J. Apatinib for the treatment of gastric cancer. Expert Opin Pharmacother 2015; 16: 117-122 [PMID: 25420417 DOI: 10.1517/14656566.2015.981526]
127. Li J, Qin S, Xu J, Guo W, Xiong J, Bai Y, Sun G, Yang Y, Wang L, Xu N, Cheng Y, Wang Z, Zheng L, Tao M, Zhu X, Ji D, Liu X, Yu H. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: Results from a randomized, placebo-controlled, parallelarm, phase II trial. J Clin Oncol 2013; 31: 3219-3225 [PMID: 23918952 DOI: 10.1200/JCO.2013.48.8585]
128. Qin S, Li J, Xu J. Phase III study of apatinib in advanced gastric cancer: A randomized, double-blind, placebo-controlled trial. J Clin Oncol 2014; 32 Suppl 5: Abstr 4003
129. Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y, Liu W, Tong J, Liu Y, Xu R, Wang Z, Wang Q, Ouyang X, Yang Y, Ba Y, Liang J, Lin X, Luo D, Zheng R, Wang X, Sun G, Wang L, Zheng L, Guo H, Wu J, Xu N, Yang J, Zhang H, Cheng Y, Wang N, Chen L, Fan Z, Sun P, Yu H. Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction. J Clin Oncol 2016; 34: 1448-1454 [PMID: 26884585 DOI: 10.1200/JCO.2015.63.5995]
130. Fan M, Zhang J, Wang Z, Wang B, Zhang Q, Zheng C, Li T, Ni C, Wu Z, Shao Z, Hu X. Phosphorylated VEGFR2 and hypertension: Potential biomarkers to indicate VEGF-dependency of advanced breast cancer in anti-angiogenic therapy. Breast Cancer Res Treat 2014; 143: 141-151 [PMID: 24292957 DOI: 10.1007/s10549-013-2793-6]
131. Apatinib got CFDA approval. Available from: URL: Http://www. inyaohui.com/news/201502/05/5059.html
132. Sutent (sunitinib maleate) FDA Approval History. Available from: URL: Http://www.drugs.com/history/sutent.html
133. Bang YJ, Kang YK, Kang WK, Boku N, Chung HC, Chen JS, Doi T, Sun Y, Shen L, Qin S, Ng WT, Tursi JM, Lechuga MJ, Lu DR, Ruiz-Garcia A, Sobrero A. Phase II study of sunitinib as secondline treatment for advanced gastric cancer. Invest New Drugs 2011; 29: 1449-1458 [PMID: 20461441 DOI: 10.1007/s10637-010- 9438-y]
134. Yi JH, Lee J, Lee J, Park SH, Park JO, Yim DS, Park YS, Lim HY, Kang WK. Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. Br J Cancer 2012; 106: 1469-1474 [PMID: 22460270 DOI: 10.1038/bjc.2012]
135. Gómez-Martín C, Salazar R, Montagut C, Gil-Martín M, Núñez JA, Puig M, Lin X, Khosravan R, Tursi JM, Lechuga MJ, Bellmunt J. A phase I, dose-finding study of sunitinib combined with cisplatin and 5-fluorouracil in patients with advanced gastric cancer. Invest New Drugs 2013; 31: 390-398 [PMID: 22615059 DOI: 10.1007/s10637-012-9830-x]
136. Lee KW, Park SR, Oh DY, Park YI, Khosravan R, Lin X, Lee SY, Roh EJ, Valota O, Lechuga MJ, Bang YJ. Phase I study of sunitinib plus capecitabine/cisplatin or capecitabine/oxaliplatin in advanced gastric cancer. Invest New Drugs 2013; 31: 1547-1558 [PMID: 24091982 DOI: 10.1007/s10637-013-0032-y]
137. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390 [PMID: 18650514 DOI: 10.1056/NEJMoa0708857]
138. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-134 [PMID: 17215530 DOI: 10.1056/NEJMoa060655]
139. Yang S, Ngo VC, Lew GB, Chong LW, Lee SS, Ong WJ, Lam WL, Thng CH, Koong HN, Ong HS, Chung A, Chow P, Lee J, Soo KC, Huynh H. AZD6244 (ARRY-142886) enhances the therapeutic efficacy of sorafenib in mouse models of gastric cancer. Mol Cancer Ther 2009; 8: 2537-2545 [PMID: 19723882 DOI: 10.1158/1535-7163.MCT-09-0213]
140. Clinical trials.gov. Phase I Study of Sorafenib With Folfox4 as Firstline Treatment in Advanced/Metastatic Gastric Cancer. Available from: URL: Https://clinicaltrials.gov/ct2/show/NCT02209441
141. Clinical trials.gov. Sorafenib Gastric Cancer Asian Phase I Study. Available from: URL: Https://clinicaltrials.gov/ct2/show/NCT00663741
142. Clinical trials.gov. Sorafenib. ICORG 06-41, V4. Available from: URL: Https://clinicaltrials.gov/ct2/show/NCT01158287
143. Sun W, Powell M, O'Dwyer PJ, Catalano P, Ansari RH, Benson AB. Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. J Clin Oncol 2010; 28: 2947-2951 [PMID: 20458043 DOI: 10.1200/JCO.2009.27.7988]
144. Clinical trials.gov. Sorafenib as a second line treatment in patients with advanced or metastatic gastric cancer. Available from: URL: Http://www.clinicaltrials.gov/ct2/show/NCT00595985
145. Martin-Richard M, Gallego R, Pericay C, Garcia Foncillas J, Queralt B, Casado E, Barriuso J, Iranzo V, Juez I, Visa L, Saigi E, Barnadas A, Garcia-Albeniz X, Maurel J. Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A GEMCAD study. Invest New Drugs 2013; 31: 1573-1579 [PMID: 24077981]
146. Clinical trials.gov. Capecitabine and Cisplatin (XP) Sorafenib in Advanced Gastric Cancer (AGC) (XP Sorafenib). Available from: URL: Https://clinicaltrials.gov/ct2/show/results/NCT00565370
147. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, Zarbá JJ, Chen M, McCann L, Pandite L, Roychowdhury DF, Hawkins RE. Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial. J Clin Oncol 2010; 28: 1061-1068 [PMID: 20100962 DOI: 10.1200/JCO.2009.23.9764]
148. van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, Schöffski P, Aglietta M, Staddon AP, Beppu Y, Le Cesne A, Gelderblom H, Judson IR, Araki N, Ouali M, Marreaud S, Hodge R, Dewji MR, Coens C, Demetri GD, Fletcher CD, Dei Tos AP, Hohenberger P. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012; 379: 1879-1886 [PMID: 22595799 DOI: 10.1016/S0140-6736(12)60651-5]
149. Dieras V, Bachelot T, Campone M, Isambert N, Joly F, Le Tourneau C, Cassier PA, Bompas E, Fumoleau P, Noal S, Orsini C, Jimenez M, Imbs DC, Chatelut E. Pazopanib (P) and cisplatin (CDDP) in patients with advanced solid tumors (PACIFIK): A UNICANCER phase I study. J Clin Oncol 2014; 32 suppl: Abstr 2583
150. Clinical trials.gov. Pazopanib and ARQ 197 for Advanced Solid Tumors. Available from: URL: Https://www.clinicaltrials.gov/ct2/show/NCT01468922
151. Clinical trials.gov. FLO/- pazopanib as first-line treatment in advanced gastric cancer (PaFLO). Available from: URL: Http://clinicaltrials.gov/ct2/show/NCT01503372
152. Clinical trials.gov. A study of pazopanib with CAPEOX in AGC patients. Available from: URL: Http://clinicaltrials.gov/ct2/show/NCT01130805
153. Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H, Hohenberger P, Leahy M, von Mehren M, Joensuu H, Badalamenti G, Blackstein M, Le Cesne A, Schöffski P, Maki RG, Bauer S, Nguyen BB, Xu J, Nishida T, Chung J, Kappeler C, Kuss I, Laurent D, Casali PG. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381: 295-302 [PMID: 23177515 DOI: 10.1016/S0140-6736(12)61857-1]
154. Stivarga (Regorafenib) FDA approval history. Available from: URL: Http://www.drugs.com/history/stivarga.html
155. Huynh H, Ong R, Zopf D. Antitumor activity of the multikinase inhibitor regorafenib in patient-derived xenograft models of gastric cancer. J Exp Clin Cancer Res 2015; 34: 132 [PMID: 26514182 DOI: 10.1186/s13046-015-0243-5]
156. Pavlakis N, Sjoquist KM, Tsobanis E. INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib (REG) in refractory advanced esophagogastric cancer (AOGC)-A study by the Australasian Gastrointestinal Trials Group (AGITG): Final overall and subgroup results. Ann Oncol 2015; 26 Suppl t4: 119
157. Clinical trials.gov. Regorafenib Second Line Treatment of Metastatic or Advanced Upper GI Cancers. Available from: URL: Https://www.clinicaltrials.gov/ct2/show/NCT02241720
158. Clinical trials.gov. FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer. Available from: URL: Https://www.clinicaltrials.gov/ct2/show/NCT01913639
159. Clinical trials.gov. Regorafenib in Combination With Paclitaxel in Advanced Oesophagogastric Carcinoma (REPEAT). Available from: URL: Https://www.clinicaltrials.gov/ct2/show/NCT02406170
160. Foulstone E, Prince S, Zaccheo O, Burns JL, Harper J, Jacobs C, Church D, Hassan AB. Insulin-like growth factor ligands, receptors, and binding proteins in cancer. J Pathol 2005; 205: 145-153 [PMID: 15641016 DOI: 10.1002/path.1712]
161. Matsubara J, Yamada Y, Nakajima TE, Kato K, Hamaguchi T, Shirao K, Shimada Y, Shimoda T. Clinical significance of insulinlike growth factor type 1 receptor and epidermal growth factor receptor in patients with advanced gastric cancer. Oncology 2008; 74: 76-83 [PMID: 18544998 DOI: 10.1159/000139127]
162. Baserga R, Peruzzi F, Reiss K. The IGF-1 receptor in cancer biology. Int J Cancer 2003; 107: 873-877 [PMID: 14601044 DOI: 10.1002/ijc.11487]
163. Attard G, Fong PC, Molife R. Phase I trial involving the pharmacodynamic (PD) study of circulating tumour cells, of CP-751,871 (C), a monoclonal antibody against the insulin-like growth factor 1 receptor (IGF-1R), with docetaxel (D) in patients (p) with advanced cancer. J Clin Oncol 2006; 24: Abstr 3023
164. Juergens H, Daw NC, Geoerger B, Ferrari S, Villarroel M, Aerts I, Whelan J, Dirksen U, Hixon ML, Yin D, Wang T, Green S, Paccagnella L, Gualberto A. Preliminary efficacy of the antiinsulin- like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma. J Clin Oncol 2011; 29: 4534-4540 [PMID: 22025154 DOI: 10.1200/JCO.2010.33.0670]
165. Goto Y, Sekine I, Tanioka M, Shibata T, Tanai C, Asahina H, Nokihara H, Yamamoto N, Kunitoh H, Ohe Y, Kikkawa H, Ohki E, Tamura T. Figitumumab combined with carboplatin and paclitaxel in treatment-naïve Japanese patients with advanced non-small cell lung cancer. Invest New Drugs 2012; 30: 1548-1556 [PMID: 21748299 DOI: 10.1007/s10637-011-9715-4]
166. Langer CJ, Novello S, Park K, Krzakowski M, Karp DD, Mok T, Benner RJ, Scranton JR, Olszanski AJ, Jassem J. Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer. J Clin Oncol 2014; 32: 2059-2066 [PMID: 24888810 DOI: 10.1200/JCO.2013.54.4932]
167. Clinical trials.gov. Study Of CP-751,871 In Combination With Sunitinib In Patients With Advanced Solid Tumors. Available from: URL: Https://www.clinicaltrials.gov/ct2/show/study/NCT00729833
168. Clinical trials.gov. CP-751,871 In Combination With Docetaxel In Advance Non-hematologic Malignancies. Available from: URL: Https://www.clinicaltrials.gov/ct2/show/NCT01653158
169. Grose R, Dickson C. Fibroblast growth factor signaling in tumorigenesis. Cytokine Growth Factor Rev 2005; 16: 179-186 [PMID: 15863033 DOI: 10.1016/j.cytogfr.2005.01.003]
170. Hattori Y, Itoh H, Uchino S, Hosokawa K, Ochiai A, Ino Y, Ishii H, Sakamoto H, Yamaguchi N, Yanagihara K, Hirohashi S, Sugimura T, Terada M. Immunohistochemical detection of K-sam protein in stomach cancer. Clin Cancer Res 1996; 2: 1373-1381 [PMID: 9816310]
171. Takeda M, Arao T, Yokote H, Komatsu T, Yanagihara K, Sasaki H, Yamada Y, Tamura T, Fukuoka K, Kimura H, Saijo N, Nishio K. AZD2171 shows potent antitumor activity against gastric cancer over-expressing fibroblast growth factor receptor 2/keratinocyte growth factor receptor. Clin Cancer Res 2007; 13: 3051-3057 [PMID: 17505008 DOI: 10.1158/1078-0432.CCR-06-2743]
172. Bang YJ, Van Cutsem E, Mansoor W. A randomized, openlabel phase II study of AZD4547 (AZD) versus Paclitaxel (P) in previously treated patients with advanced gastric cancer (AGC) with Fibroblast Growth Factor Receptor 2 (FGFR2) polysomy or gene amplification (amp): SHINE study. J Clin Oncol 2015; 33 Suppl: Abstr 4014
173. Dienstmann R, Bahleda R, Adamo B, Rodon J, Varga A, Gazzah A, Platero S, Smit H, Perera T, Zhong B, Stuyckens K, Elsayed Y, Takimoto C, Peddareddigari V, Tabernero J, Luo FR, Soria JR. Abstract CT325: First in human study of JNJ-42756493, a potent pan fibroblast growth factor receptor (FGFR) inhibitor in patients with advanced solid tumors. Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. Cancer Res 2014; 74: CT325 [DOI: 10.1158/1538-7445.AM2014-CT325]
174. Nakamura K, Yashiro M, Matsuoka T, Tendo M, Shimizu T, Miwa A, Hirakawa K. A novel molecular targeting compound as K-samII/FGF-R2 phosphorylation inhibitor, Ki23057, for Scirrhous gastric cancer. Gastroenterology 2006; 131: 1530-1541 [PMID: 17101326 DOI: 10.1053/j.gastro.2006.08.030]
175. Qiu H, Yashiro M, Zhang X, Miwa A, Hirakawa K. A FGFR2 inhibitor, Ki23057, enhances the chemosensitivity of drugresistant gastric cancer cells. Cancer Lett 2011; 307: 47-52 [PMID: 21482024 DOI: 10.1016/j.canlet.2011.03.015]
176. Trudel S, Li ZH, Wei E, Wiesmann M, Chang H, Chen C, Reece D, Heise C, Stewart AK. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4; 14) multiple myeloma. Blood 2005; 105: 2941-2948 [PMID: 15598814 DOI: 10.1182/blood-2004-10-3913]
177. Huynh H, Chow PK, Tai WM, Choo SP, Chung AY, Ong HS, Soo KC, Ong R, Linnartz R, Shi MM. Dovitinib demonstrates antitumor and antimetastatic activities in xenograft models of hepatocellular carcinoma. J Hepatol 2012; 56: 595-601 [PMID: 22027573 DOI: 10.1016/j.jhep.2011.09.017]
178. Huynh H, Ngo VC, Fargnoli J, Ayers M, Soo KC, Koong HN, Thng CH, Ong HS, Chung A, Chow P, Pollock P, Byron S, Tran E. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin Cancer Res 2008; 14: 6146-6153 [PMID: 18829493 DOI: 10.1158/1078-0432.CCR-08-0509]
179. Cai ZW, Zhang Y, Borzilleri RM, Qian L, Barbosa S, Wei D, Zheng X, Wu L, Fan J, Shi Z, Wautlet BS, Mortillo S, Jeyaseelan R, Kukral DW, Kamath A, Marathe P, D'Arienzo C, Derbin G, Barrish JC, Robl JA, Hunt JT, Lombardo LJ, Fargnoli J, Bhide RS. Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2- methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6- yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215). J Med Chem 2008; 51: 1976-1980 [PMID: 18288793 DOI: 10.1021/jm7013309]
180. Ayers M, Fargnoli J, Lewin A, Wu Q, Platero JS. Discovery and validation of biomarkers that respond to treatment with brivanib alaninate, a small-molecule VEGFR-2/FGFR-1 antagonist. Cancer Res 2007; 67: 6899-6906 [PMID: 17638901 DOI: 10.1158/0008-5472.CAN-06-4555]
181. Bhide RS, Cai ZW, Zhang YZ, Qian L, Wei D, Barbosa S, Lombardo LJ, Borzilleri RM, Zheng X, Wu LI, Barrish JC, Kim SH, Leavitt K, Mathur A, Leith L, Chao S, Wautlet B, Mortillo S, Jeyaseelan R, Kukral D, Hunt JT, Kamath A, Fura A, Vyas V, Marathe P, D'Arienzo C, Derbin G, Fargnoli J. Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5- yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor. J Med Chem 2006; 49: 2143-2146 [PMID: 16570908 DOI: 10.1021/jm051106d]
182. Finn RS, Kang YK, Mulcahy M, Polite BN, Lim HY, Walters I, Baudelet C, Manekas D, Park JW. Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2012; 18: 2090-2098 [PMID: 22238246 DOI: 10.1158/1078-0432.CCR-11-1991]
183. Clinical trials.gov. Dovitinib for Gastric Cancer With FGFR2 Amplification. Available from: URL: Https://www.clinicaltrials. gov/ct2/show/NCT01719549
184. Clinical trials.gov. Open-Label, Dose-Escalation Study of INCB054828 in Subjects With Advanced Malignancies. Available from: URL: Https://www.clinicaltrials.gov/ct2/show/NCT02393248
185. Clinical trials.gov. Combination of Brivanib With 5-Fluorouracil/Leucovorin (5FU/LV) and5-Fluorouracil/Leucovorin/Irinotecan(FOLFIRI). Available from: URL: Https://www. clinicaltrials.gov/ct2/show/NCT01046864
186. Nakajima M, Sawada H, Yamada Y, Watanabe A, Tatsumi M, Yamashita J, Matsuda M, Sakaguchi T, Hirao T, Nakano H. The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 1999; 85: 1894-1902 [PMID: 10223227]
187. Lordick F. Targeting the HGF/MET pathway in gastric cancer. Lancet Oncol 2014; 15: 914-916 [PMID: 24965570]
188. Oliner KS, Tang R, Anderson A, Lan Y, Iveson T, Donehower RC, Jiang Y, Dubey S, Loh E. Evaluation of MET pathway biomarkers in a phase II study of rilotumumab (R, AMG 102) or placebo (P) in combination with epirubicin, cisplatin, and capecitabine (ECX) in patients (pts) with locally advanced or metastatic gastric (G) or esophagogastric junction (EGJ) cancer. J Clin Oncol 2012; 30: Abstr 4005
189. Iveson T, Donehower RC, Davidenko I, Tjulandin S, Deptala A, Harrison M, Nirni S, Lakshmaiah K, Thomas A, Jiang Y, Zhu M, Tang R, Anderson A, Dubey S, Oliner KS, Loh E. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: An open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study. Lancet Oncol 2014; 15: 1007-1018 [PMID: 24965569 DOI: 10.1016/S1470-2045(14)70023-3]
190. Cunningham D, Tebbutt NC, Davidenko I, Murad AM, AIBatran SE, IIson DH, Tjulandin S, Gotovkin E, Karaszewska B, Bondarenko I, Tejani MA, Udrea AA, Tehfe MA, Baker N, Oliner KS, Zhang Y, Hoang T, Sidhu R, Catenacci DVT. Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced METpositive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study. J Clin Oncol 2015; 33 Suppl: Abstr 4000
191. Shah MA, Bang YJ, Lordicketal F. MET Gastric: A phase III study of onartuzumab plus mFOLFOX6 in patients with metastatic HER2-negative (HER2-) and MET-positive (MET ) adenocarcinoma of the stomach or gastroesophageal junction (GEC). J Clin Oncol 2015; 33 Suppl: Abstr 4012
192. Kwak F. Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor. J Clin Oncol 2009; 27 Suppl: Abstr 15
193. Kataoka Y, Mukohara T, Tomioka H, Funakoshi Y, Kiyota N, Fujiwara Y, Yashiro M, Hirakawa K, Hirai M, Minami H. Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking interreceptor tyrosine kinase networks. Invest New Drugs 2012; 30: 1352-1360 [PMID: 21655918 DOI: 10.1007/s10637-011-9699-0]
194. Jhawer M, Kindler HL, Wainberg Z, Ford J, Kunz P, Tang L, McCallum S, Kallender H, Shah MA. Assessment of two dosing schedules of GSK1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in metastatic gastric cancer (GC): Interim results of a multicenter phase II study. J Clin Oncol 2009; 27: Abstr 4502
195. Shah MA, Wainberg ZA, Catenacci DV, Hochster HS, Ford J, Kunz P, Lee FC, Kallender H, Cecchi F, Rabe DC, Keer H, Martin AM, Liu Y, Gagnon R, Bonate P, Liu L, Gilmer T, Bottaro DP. Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer. PLoS One 2013; 8: E54014 [PMID: 23516391 DOI: 10.1371/journal.pone.0054014]
196. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2: 489-501 [PMID: 12094235 DOI: 10.1038/nrc839]
197. Yap TA, Garrett MD, Walton MI, Raynaud F, de Bono JS, Workman P. Targeting the PI3K-AKT-mTOR pathway: Progress, pitfalls, and promises. Curr Opin Pharmacol 2008; 8: 393-412 [PMID: 18721898]
198. Yu HG, Ai YW, Yu LL, Zhou XD, Liu J, Li JH, Xu XM, Liu S, Chen J, Liu F, Qi YL, Deng Q, Cao J, Liu SQ, Luo HS, Yu JP. Phosphoinositide 3-kinase/Akt pathway plays an important role in chemoresistance of gastric cancer cells against etoposide and doxorubicin induced cell death. Int J Cancer 2008; 122: 433-443 [PMID: 17935137 DOI: 10.1002/ijc.23049]
199. Al-Batran SE, Ducreux M, Ohtsu A. mTOR as a therapeutic target in patients with gastric cancer. Int J Cancer 2012; 130: 491-496 [PMID: 21898386 DOI: 10.1002/ijc.26396]
200. Alvarado Y, Mita MM, Vemulapalli S, Mahalingam D, Mita AC. Clinical activity of mammalian target of rapamycin inhibitors in solid tumors. Target Oncol 2011; 6: 69-94 [PMID: 21541789 DOI: 10.1007/s11523-011-0178-5]
201. Dabney R, Devine R, Sein N, George B. New agents in renal cell carcinoma. Target Oncol 2014; 9: 183-193 [PMID: 24243495 DOI: 10.1007/s11523-013-0303-8]
202. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Öberg K. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 514-523 [PMID: 21306238 DOI: 10.1056/NEJMoa1009290]
203. Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, Witt O, Kohrman MH, Flamini JR, Wu JY, Curatolo P, de Vries PJ, Whittemore VH, Thiele EA, Ford JP, Shah G, Cauwel H, Lebwohl D, Sahmoud T, Jozwiak S. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): A multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2013; 381: 125-132 [PMID: 23158522 DOI: 10.1016/S0140-6736(12)61134-9]
204. Hart CD, Migliaccio I, Malorni L, Guarducci C, Biganzoli L, Di Leo A. Challenges in the management of advanced, ER-positive, HER2-negative breast cancer. Nat Rev Clin Oncol 2015; 12: 541-552 [PMID: 26011489 DOI: 10.1038/nrclinonc.2015.99]
205. Okamoto I, Doi T, Ohtsu A, Miyazaki M, Tsuya A, Kurei K, Kobayashi K, Nakagawa K. Phase I clinical and pharmacokinetic study of RAD001 (everolimus) administered daily to Japanese patients with advanced solid tumors. Jpn J Clin Oncol 2010; 40: 17-23 [PMID: 19783551 DOI: 10.1093/jjco/hyp120]
206. Doi T, Muro K, Boku N, Yamada Y, Nishina T, Takiuchi H, Komatsu Y, Hamamoto Y, Ohno N, Fujita Y, Robson M, Ohtsu A. Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer. J Clin Oncol 2010; 28: 1904-1910 [PMID: 20231677 DOI: 10.1200/JCO.2009.26.2923]
207. Van Cutsem E, Yeh KH, Bang YJ, Shen L, Ajani JA, Bai YX, Chung HC, Pan HM, Chin K, Muro K, Kim YH, Smith H, Costantini C, Musalli S, Rizvi S, Sahmoud T, Ohtsu A. Phase III trial of everolimus (EVE) in previously treated patients with advanced gastric cancer (AGC): GRANITE-1. J Clin Oncol 2012; 30: Abstr LBA3
208. Ohtsu A, Ajani JA, Bai YX, Bang YJ, Chung HC, Pan HM, Sahmoud T, Shen L, Yeh KH, Chin K, Muro K, Kim YH, Ferry D, Tebbutt NC, Al-Batran SE, Smith H, Costantini C, Rizvi S, Lebwohl D, Van Cutsem E. Everolimus for previously treated advanced gastric cancer: Results of the randomized, double-blind, phase III GRANITE-1 study. J Clin Oncol 2013; 31: 3935-3943 [PMID: 24043745 DOI: 10.1200/JCO.2012.48.3552]
209. Clinical trials.gov. Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors. Available from: URL: Https://www.clinicaltrials.gov/ct2/show/NCT01522820
210. Underhill C, Toulmonde M, Bonnefoi H. A review of PARP inhibitors: From bench to bedside. Ann Oncol 2011; 22: 268-279 [PMID: 20643861 DOI: 10.1093/annonc/mdq322]
211. Bang YJ, Im SA, Lee KW, Cho JY, Song EK, Lee KH, Kim YH, Park JO, Chun HG, Zhang DY, Fielding A, Rowbottom J, Hodgson D, O'Connor MJ, Yin X, Kim WH. Olaparib plus paclitaxel in patients with recurrent or metastatic gastric cancer: A randomized, double-blind phase II study. J Clin Oncol 2013; 31: Abstr 4013
212. Bang YJ, Im SA, Lee KW, Cho JY, Song EK, Lee KH, Kim YH, Park JO, Chun HG, Zang DY, Fielding A, Rowbottom J, Hodgson D, O'Connor MJ, Yin X, Kim WH. Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer. J Clin Oncol 2015; 33: 3858-3865 [PMID: 26282658 DOI: 10.1200/JCO.2014.60.0320]
213. Kubota E, Williamson CT, Ye R, Elegbede A, Peterson L, Lees- Miller SP, Bebb DG. Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines. Cell Cycle 2014; 13: 2129-2137 [PMID: 24841718 DOI: 10.4161/cc.29212]
214. Clinical trials.gov. Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer. Available from: URL: Https://www.clinicaltrials.gov/ct2/show/NCT01924533
215. Clinical trials.gov. Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents. Available from: URL: Https://clinicaltrials.gov/ct2/show/NCT02264678
216. Clinical trials.gov. Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor. Available from: URL: Https://www.clinicaltrials. gov/ct2/show/NCT01123876
217. Kanagavel D, Fedyanin M, Tryakin A, Tjulandin S. Second-line treatment of metastatic gastric cancer: Current options and future directions. World J Gastroenterol 2015; 21: 11621-11635 [PMID: 26556991 DOI: 10.3748/wjg.v21.i41.11621]
218. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Elassaiss-Schaap J, Algazi A, Mateus C, Boasberg P, Tumeh PC, Chmielowski B, Ebbinghaus SW, Li XN, Kang SP, Ribas A. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369: 134-144 [PMID: 23724846 DOI: 10.1056/NEJMoa1305133]
219. Keir ME, Liang SC, Guleria I, Latchman YE, Qipo A, Albacker LA, Koulmanda M, Freeman GJ, Sayegh MH, Sharpe AH. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med 2006; 203: 883-895 [PMID: 16606670 DOI: 10.1084/jem.20051776]
220. Culver ME, Gatesman ML, Mancl EE, Lowe DK. Ipilimumab: A novel treatment for metastatic melanoma. Ann Pharmacother 2011; 45: 510-519 [PMID: 21505108 DOI: 10.1345/aph.1P651]
221. Clinical trials.gov. Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC). Available from: URL: Https://www. clinicaltrials.gov/show/NCT00527735
222. Clinical trials.gov. First-Line Gemcitabine, Cisplatin Ipilimumab for Metastatic Urothelial Carcinoma. Available from: URL: Https://www.clinicaltrials.gov/show/NCT01524991
223. Clinical trials.gov. Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer. Available from: URL: Https://www.clinicaltrials.gov/show/NCT00323882
224. Clinical trials.gov. An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line Chemotherapy. Available from: URL: Https://www.clinicaltrials.gov/ct2/show/NCT01585987
225. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366: 2455-2465 [PMID: 22658128 DOI: 10.1056/NEJMoa1200694]
226. Clinical trials.gov. Multiple Ascending Dose (MDX1105-01) (Anti-PDL1). Available from: URL: Https://clinicaltrials.gov/show/NCT00729664
227. Clinical trials.gov. A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab in Subjects With Advanced or Metastatic Solid Tumors. Available from: URL: Https://www.clinicaltrials.gov/ct2/show/NCT01928394
228. Le DT, Bendell JC, Calvo E, Kim JW, Ascierto PA, Sharma P, Ott PA, Bono P, Jaeger D, Evans TRJ, De Braud FG, Chau I, Christensen O, Harbison C, Lin CS, Janjigian YY. Safety and activity of nivolumab monotherapy in advanced and metastatic (A/M) gastric or gastroesophageal junction cancer (GC/GEC): Results from the CheckMate-032 study. 2016 Gastrointestinal Cancers Symposium. J Clin Oncol 2016; 34 Suppl 4S: Abstr 6
229. Clinical trials.gov. Study of ONO-4538 in Unresectable Advanced or Recurrent Gastric Cancer. Available from: URL: Https://www. clinicaltrials.gov/ct2/show/NCT02267343
230. Muro K, Bang Y, Shankaran V. LBA15 A phase 1b study of pembrolizumab (PEMBRO; MK-3475) in patients (PTS) with advanced gastric cancer. Ann Oncol 2014; 25: 1-41 [DOI: 10.1093/annonc/mdu438.15]
231. Clinical trials.gov. Study of Pembrolizumab (MK-3475) as First- Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062). Available from: URL: Https://clinicaltrials.gov/ct2/show/NCT02494583
232. Clinical trials.gov. A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059). Available from: URL: Https://clinicaltrials.gov/ct2/show/NCT02335411
233. Clinical trials.gov. Study of Pembrolizumab in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine: Integration of Molecular Subtypes Through Integrative Genomic Analysis. Available from: URL: Https://clinicaltrials.gov/ct2/show/NCT02589496
234. Clinical trials.gov. Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer. Available from: URL: Https://clinicaltrials.gov/ct2/show/NCT02689284
235. Clinical trials.gov. Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer (PembroMab). Available from: URL: Https://clinicaltrials.gov/ct2/show/NCT02318901
236. Clinical trials.gov. A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC or Transitional Cell Carcinoma of the Urothelium. Available from: URL: Https://clinicaltrials.gov/ct2/show/NCT02443324
237. Clinical trials.gov. A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors. Available from: URL: Https://clinicaltrials.gov/ct2/show/NCT02452424
238. Clinical trials.gov. Phase 1b Open-Label Study of PEGPH20 With Pembrolizumab. Available from: URL: Https://clinicaltrials.gov/ct2/show/NCT02563548
239. Lutzky J, Antonia SJ, Blake-Haskins A, Li X, Robbins PB, Shalabi AM, Vasselli J, Ibrahim RA, Khleif S, Segal NH. A phase 1 study of MEDI4736, an anti-PD-L1 antibody, in patients with advanced solid tumors. J Clin Oncol 2014; 32: Abstr 3001
240. Clinical trials.gov. Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors. Available from: URL: Https://clinicaltrials.gov/ct2/show/NCT02658214
241. Clinical trials.gov. A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma. Available from: URL: Https://clinicaltrials.gov/ct2/show/NCT02340975
242. Clinical trials.gov. A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors. Available from: URL: Https://clinicaltrials.gov/ct2/show/NCT02318277
243. Clinical trials.gov. Planning Treatment for Oesophago-gastric Cancer: A Maintenance Therapy Trial (PLATFORM). Available from: URL: Https://clinicaltrials.gov/ct2/show/NCT02678182
244. Clinical trials.gov. A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies. Available from: URL: Https://clinicaltrials. gov/ct2/show/NCT02572687
245. Clinical trials.gov. Phase 1 Study of MLN0264 in Adult Patients With Advanced Gastrointestinal Malignancies Expressing Guanylyl Cyclase C. Available from: URL: Https://clinicaltrials.gov/show/NCT01577758
246. Messersmith W, Almhanna K, Rodon J, Cruz C, Ryan D, Jung JA, Fasanmade A, Wyant T, Kalebic T. PD-0032MLN0264, an investigational, first-in-class antibodydrug conjugate targeting guanylyl cyclase C (GCC): First in-human study in patients with advanced gastrointestinal malignancies. Ann Oncol 2013; 24: Piv36
247. Clinical trials.gov. A Study of MLN0264 in Patients With Cancer of the Stomach or Gastroesophageal Junction. Available from: URL: Https://clinicaltrials.gov/ct2/show/NCT02202759
248. Clinical trials.gov. MLN0264 in Previously Treated Asian Patients With Advanced Gastrointestinal Carcinoma or Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Guanylyl Cyclase C. Available from: URL: Https://clinicaltrials.gov/ct2/show/NCT02391038
249. Lim S, Kaldis P. Cdks, cyclins and CKIs: Roles beyond cell cycle regulation. Development 2013; 140: 3079-3093 [PMID: 23861057 DOI: 10.1242/dev.091744]
250. Holkova B, Supko JG, Ames MM, Reid JM, Shapiro GI, Perkins EB, Ramakrishnan V, Tombes MB, Honeycutt C, McGovern RM, Kmieciak M, Shrader E, Wellons MD, Sankala H, Doyle A, Wright J, Roberts JD, Grant S. A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2. Clin Cancer Res 2013; 19: 1873-1883 [PMID: 23515411 DOI: 10.1158/1078-0432.CCR-12-2926]
251. Schwartz GK, Ilson D, Saltz L, O'Reilly E, Tong W, Maslak P, Werner J, Perkins P, Stoltz M, Kelsen D. Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. J Clin Oncol 2001; 19: 1985-1992 [PMID: 11283131]
252. Clinical trials.gov. Irinotecan Hydrochloride With or Without Alvocidib in Treating Patients With Advanced Stomach or Gastroesophageal Junction Cancer That Cannot Be Removed By Surgery. Available from: URL: Https://clinicaltrials.gov/ct2/show/NCT00991952
253. Xu L, Qu X, Luo Y, Zhang Y, Liu J, Qu J, Zhang L, Liu Y. Epirubicin enhances TRAIL-induced apoptosis in gastric cancer cells by promoting death receptor clustering in lipid rafts. Mol Med Rep 2011; 4: 407-411 [PMID: 21468584 DOI: 10.3892/mmr.2011.439]
254. Cusack JC. Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib. Cancer Treat Rev 2003; 29 Suppl 1: 21-31 [PMID: 12738240]
255. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006; 441: 431-436 [PMID: 16724054 DOI: 10.1038/nature04870]
256. Berenson JR, Yang HH, Sadler K, Jarutirasarn SG, Vescio RA, Mapes R, Purner M, Lee SP, Wilson J, Morrison B, Adams J, Schenkein D, Swift R. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. J Clin Oncol 2006; 24: 937-944 [PMID: 16418495 DOI: 10.1200/JCO.2005.03.2383]
257. Kane RC, Dagher R, Farrell A, Ko CW, Sridhara R, Justice R, Pazdur R. Bortezomib for the treatment of mantle cell lymphoma. Clin Cancer Res 2007; 13: 5291-5294 [PMID: 17875757 DOI: 10.1158/1078-0432.CCR-07-0871]
258. Fujita T, Doihara H, Washio K, Ino H, Murakami M, Naito M, Shimizu N. Antitumor effects and drug interactions of the proteasome inhibitor bortezomib (PS341) in gastric cancer cells. Anticancer Drugs 2007; 18: 677-686 [PMID: 17762396]
259. Bae SH, Ryoo HM, Kim MK, Lee KH, Sin JI, Hyun MS. Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapeutic agents in gastric cancer cell lines. Oncol Rep 2008; 19: 1027-1032 [PMID: 18357392 DOI: 10.3892/or.19.4.1027]
260. Ocean AJ, Christos P, Sparano JA, Shah MA, Yantiss RK, Cheng J, Lin J, Papetti M, Matulich D, Schnoll-Sussman F, Besanceney- Webler C, Xiang J, Ward M, Dilts KT, Keresztes R, Holloway S, Chen EX, Wright JJ, Lane ME. Phase II trial of bortezomib alone or in combination with irinotecan in patients with adenocarcinoma of the gastroesophageal junction or stomach. Invest New Drugs 2014; 32: 542-548 [PMID: 24526575 DOI: 10.1007/s10637-014-0070-0]
261. Jatoi A, Dakhil SR, Foster NR, Ma C, Rowland KM, Moore DF, Jaslowski AJ, Thomas SP, Hauge MD, Flynn PJ, Stella PJ, Alberts SR. Bortezomib, paclitaxel, and carboplatin as a firstline regimen for patients with metastatic esophageal, gastric, and gastroesophageal cancer: Phase II results from the North Central Cancer Treatment Group (N044B). J Thorac Oncol 2008; 3: 516-520 [PMID: 18449005 DOI: 10.1097/JTO.0b013e31816de276]
262. Shah MA, Power DG, Kindler HL, Holen KD, Kemeny MM, Ilson DH, Tang L, Capanu M, Wright JJ, Kelsen DP. A multicenter, phase II study of bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma. Invest New Drugs 2011; 29: 1475-1481 [PMID: 20574790]
263. Zhang QW, Liu L, Chen R, Wei YQ, Li P, Shi HS, Zhao YW. Matrix metalloproteinase-9 as a prognostic factor in gastric cancer: A meta-analysis. Asian Pac J Cancer Prev 2012; 13: 2903-2908 [PMID: 22938481]
264. He L, Chu D, Li X, Zheng J, Liu S, Li J, Zhao Q, Ji G. Matrix metalloproteinase-14 is a negative prognostic marker for patients with gastric cancer. Dig Dis Sci 2013; 58: 1264-1270 [PMID: 23314917 DOI: 10.1007/s10620-012-2513-9]
265. Bramhall SR, Hallissey MT, Whiting J, Scholefield J, Tierney G, Stuart RC, Hawkins RE, McCulloch P, Maughan T, Brown PD, Baillet M, Fielding JW. Marimastat as maintenance therapy for patients with advanced gastric cancer: A randomised trial. Br J Cancer 2002; 86: 1864-1870 [PMID: 12085177]
266. Sampieri CL, León-Córdoba K, Remes-Troche JM. Matrix metalloproteinases and their tissue inhibitors in gastric cancer as molecular markers. J Cancer Res Ther 2013; 9: 356-363 [PMID: 24125966 DOI: 10.4103/0973-1482.119302]